What pricing and reimbursement policies to use for off-patent biologicals? - Results from the EBE 2014 biological medicines policy survey

GaBI Journal

Volumn 4, Issue 1, 2015, Pages 17-24

  Acha, Virginia ^a   Allin, Piers ^b   Bergunde, Stefan ^c   Bisordi, Fabio ^d   Roediger, Alexander ^e  

^a Global Regulatory and R and D Policy Europe   (United Arab Emirates)

^b European Biopharmaceutical Enterprises   (United Arab Emirates)

^c ABBVIE INC   (United States)

^d F Hoffmann La Roche Ltd   (United Arab Emirates)

^e Merck ESD EU MSD Europe Inc   (Belgium)

Author keywords

Biological medicines; Biosimilars; Off patent market; Pricing and reimbursement policy

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT;

ARTICLE; DESCRIPTIVE RESEARCH; DRUG COST; DRUG LEGISLATION; DRUG MARKETING; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; NORWAY; PRESCRIPTION; REIMBURSEMENT; SERBIA; SWITZERLAND;

EID: 85008259058     PISSN: 20336403     EISSN: 20336772     Source Type: Journal    
DOI: 10.5639/gabij.2015.0401.006     Document Type: Article

References (36)

1. European Commission. Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. Economic Papers 461. 2012 [homepage on the Internet]. 2012 Sep 27 [cited 2015 Feb 11]. Available from: http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf
2. European Union. Eur-Lex. Treaty of the Functioning of the European Union, Art. 168(7); Official Journal (9.5.2008) C115/47-199 [homepage on the Internet]. [cited 2015 Feb 11]. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:12012E/TXT
3. European Generics medicines Association. Napolitano S. EGA Fact Sheet on generic medicines. Every year Generic medicines bring savings of € 35 BN to the EU 27 [homepage on the Internet]. 2013 Nov 13 [cited 2015 Feb 11]. Available from: http://www.egagenerics.com/images/EGA_factsheet_09.pdf
4. European Commission. IMS. Dunn C. Biosimilar accessible market: size and biosimilar penetration. Prepared for EFPIA-EGA-EuropaBio, April 2012 [homepage on the Internet]. [cited 2015 Feb 11]. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_imsstudy_en.pdf
5. IMS Health. Assessing biosimilar uptake and competition in European markets. October 2014 [homepage on the Internet]. 2014 Oct 8 [cited 2015 Feb 11]. Available from: http://www.imshealth.com/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Insights/Assessing_biosimilar_uptake_and_competition_in_European_markets.pdf
6. European Medicines Agency. European public assessment reports [homepage on the Internet]. [cited 2015 Feb 11]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit
7. Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol. 2014;32(10):992-1000.
8. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Feb 11]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
9. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). EMA/837805/2011. 27 September 2012 [homepage on the Internet]. 2012 Sep 27 [cited 2015 Feb 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf
10. Weise M, et al. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191-6.
11. European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04 Rev 1. 23 October 2014 [homepage on the Internet]. 2014 Oct 30 [cited 2015 Feb 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
12. European Medicines Agency. EMA Procedural advice for users of the Centralised Procedure for Similar Biological Medicinal Products applications. EMA/940451/2011. October 2014 [homepage on the Internet]. 2014 Oct 29 [cited 2015 Feb 11]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125166.pdf
13. European Commission. What you need to know about biosimilar medicinal products. A consensus information document [homepage on the Internet]. 2013 Apr 24 [cited 2015 Feb 11]. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf
14. Farfan-Portet MI, Gerkens S, Lepage-Nefkens I, Vinck I, Hulstaert F. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ. 2014;15(3):223-8.
15. European Generic medicines Association. GfK Market Access. Factors supporting a sustainable european biosimilar medicines market [homepage on the Internet]. 2014 Sep 9 [cited 2015 Feb 11]. Available from: http://www.egagenerics.com/index.php/publications/342-gfk-final-report-factors-supporting-a-sustainable-european-biosimilar-medicines-market
16. Conseil Consitutionnel. Décision n° 2013-682 DC du 19 décembre 2013 [homepage on the Internet]. [cited 2015 Feb 11]. Available from: http://www.conseil-constitutionnel.fr/decision/2013/2013-682-dc/decision-n-2013-682-dc-du-19-december-2013.138972.html
17. European Biopharmaceutical Enterprises. EBE statement on French substitution policy. 24 January 2014 [homepage on the Internet]. 2014 Jan 24 [cited 2015 Feb 11]. Available from: http://www.ebe-biopharma.eu/newsroom/54/22/EBE-statement-on-French-substitution-policy
18. European Commission. Report on a biologics workshop in Warsaw on 13 November 2014. [Biosimilar medicines can be treated as generic medicines with a wider scope of research in comparison to relation to the reference medicines, and therefore they can be applied interchangeably - convinced Igor Radziewicz-Winnicki, Undersecretary of State in the Ministry of Health]. In Polish. [cited 2015 Feb 11]. Available from: http://ec.europa.eu/polska/news/141119_leki_pl.htm
19. Ministerstwo Zdrowia. Komunikat MZ-PLA-460-16300-118/BRB/14. 10 June 2014. Pismo MZ-PLA-460-15149-316/BRB/14. Wedlug rozdzielnika. 14 April 2014. [homepage on the Internet]. In Polish. [cited 2015 Feb 11]. Available from: http://www.nfz-wroclaw.pl/download.ashx?id=/45418/pisma%20MZ%20ws%20lek%F3w%20biopodobnych.pdf
20. GKV Spitzenverband. Rahmenvertrag nach §129 Absatz 2 SGB V, Paragraph 4(1), in connection with attachment 1 of the Framework Agreement on Medicinal Products Supply pursuant to Sec. 129 para 2 SGB V. 15 June 2012 [homepage on the Internet]. 2012 Jun 19 [cited 2015 Feb 11]. Available from: http://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/rahmenvertraege/apotheken/AM_20120615_S_RVtg_129_Abs2.pdf
21. Agenzia Italiana del Farmaco. Position Paper sui farmaci biosimilari (28/05/2013) [homepage on the Internet]. 2013 May 27 [cited 2015 Feb 11]. Available from: http://www.agenziafarmaco.com/it/content/position-paper
22. Agencia Estatal Boletín Oficial del Estado. Spain: Orden SCO/ 2874/2007 of 28 September, Article 1 [homepage on the Internet]. [cited 2015 Feb 11]. Available from: http://www.boe.es/diario_boe/txt.php?id=BOE-A-2007-17420
23. Dylst P, et al. Reference pricing systems in Europe: characteristics and consequences. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012;1(3-4):127-31. doi:10.5639/gabij.2012.0103-4.028
24. Jusline. Rezeptpflichtgesetz, Art. 3 (1c) [homepage on the Internet]. [cited 2015 Feb 11]. Available from: http://www.jusline.at/Rezeptpflichtgesetz_(RezPG).html
25. Österreichische Apothekerkammer. Apothekergesamtvertrag, Art. 2 [homepage on the Internet]. [cited 2015 Feb 11]. Available from: http://www.apotheker.or.at/internet/OEAK/NewsPresse_1_0_0a.nsf/agentEmergency!OpenAgent&p=4E4DD0F8172AD880C1257142002721F3&fsn=fsStartHomeFachinfo&iif=0
26. European Parliament. Kanavos P, et al. Differences in costs of and access to pharmaceutical products in the EU. 2010 [homepage on the Internet]. 2013 Mar 24 [cited 2015 Feb 11]. Available from: http://www.europarl.europa.eu/RegData/etudes/etudes/join/2011/451481/IPOL-ENVI_ET(2011)451481_EN.pdf
27. Gesundheit Österreich GmbH (GOEG) WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Bouvy J, Vogler S. Background Paper 8.3. Pricing and reimbursement policies: impacts on innovation. 2013 [homepage on the Internet]. 2013 Jun 28 [cited 2015 Feb 11]. Available from: http://whocc.goeg.at/Literaturliste/Dokumente/FurtherReading/Bouvy_PriorityMedicines_2013_BP8_3_pricing.pdf
28. World Health Organization. Kaplan W, et al. Priority Medicines for Europe and the World. 2013 Update [homepage on the Internet]. 2013 Jul 8 [cited 2015 Feb 11]. Available from: http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf
29. EU Clinical Trials Register. Clinical trials for 2014-002056-40 [homepage on the Internet]. 2015 Feb 11 [cited 2015 Feb 11]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002056-40
30. European Biopharmaceutical Enterprises. EBE Position Paper on tendering of biologicals, including biosimilars. 21 May 2012 [homepage on the Internet]. [cited 2015 Feb 11]. Available from: http://www.ebe-biopharma.eu/documents/3/22/EBE-Position-Paper-on-Tendering-of-Biologicals-including-Biosimilars
31. EuropaBio. EuropaBio's position on tendering practices in biological medicines [homepage on the Internet]. 2010 Nov 19 [cited 2015 Feb 11]. Available from: http://www.europabio.org/sites/default/files/position/europabio_position_on_tendering_practices.pdf
32. Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Nat Rev Drug Discov. 2014;13(2):99-100.
33. EuropaBio. Pan-European survey calls for a shift in policy for biosimilars. 18 March 2010 [homepage on the Internet]. 2015 Feb 11 [cited 2015 Feb 11]. Available from: http://www.europabio.org/press/pan-european-survey-calls-shift-policy-biosimilars
34. Leopold C, et al. Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Bull World Health Organ. 2014;92(9):630-40D.
35. Gesundheit Österreich GmbH (GOEG), WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies (2015), Glossary; [cited 2015 Feb 11]. Available from: http://whocc.goeg.at/Glossary/PreferredTerms
36. European Biopharmaceutical Enterprises. EBE Position paper on recommendations on the use of biological medicinal products: substitution and related healthcare policies. http://www.ebe-biopharma.eu/priorities/biosimilars